Ferozsons Laboratories Limited · PSX:FEROZ
Ferozsons Laboratories — Investor Presentation (November 2024)
21 slides from Ferozsons Laboratories's investor presentation, Nov 27, 2024
Slide 1: Corporate Briefing Session
Corporate Briefing Session Wednesday, November 27, 2024
Slide 2: Contents
CONTENTS 1 Company Profile 4 Financial Performance Collaborations and Questions and 2 Product Portfolio 5 Answers Session Pharmaceutical 3 Industry Highlights PEOPLE TRUST US
Slide 3: Agenda
AGENDA 1. Company Profile 2 Collaborations and Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session
Slide 4: Company Information
COMPANY INFORMATION Incorporation Enlistment Principle Business Patient - Centricity First Pakistani Primarily Engaged We, being a Patient Incorporated in Pharmaceutical Co. in the Manufacture, Centric Company, 1954 as Listed on Stock Imports and Sale of take Pride in Private Limited Exchange in 196
Slide 5: Our Values
OUR VALUES PUTTING PATIENTS FIRST Our purpose for existence and ultimate measure of success is our impact on the improvement of human lives. All our activities are built around this central philosophy EXCELLENCE TRUSTWORTHINESS We are committed to a We work hard every day to culture of Excellence an
Slide 6: Corporate Structure
CORPORATE STRUCTURE Ferozsons Laboratories Limited BF Biosciences Ltd - Farmacia Subsidiary Company Retail Venture – 57.36% Holding 98% Partnership Interest PEOPLE TRUST US
Slide 7: Manufacturing Capabilities
MANUFACTURING CAPABILITIES cGMP Compliant Manufacturing Facilities: We have two cGMP compliant manufacturing facilities in Pakistan, to cater the production of tablets, capsules, syrups, suspensions, ointments and injectables. Maintaining Highest Quality Standards: In order to maintain quality stand
Slide 8: Manufacturing Capabilities
MANUFACTURING CAPABILITIES Ferozsons - Pharmaceutical Manufacturing Unit, Nowshera PEOPLE TRUST US
Slide 9: Clean Energy Initiatives
CLEAN ENERGY INITIATIVES One-megawatt solar power plant fully Another one-megawatt solar power plant under final stages of operational. installation, financed through SBP Renewable Energy Scheme. PEOPLE TRUST US
Slide 10: Corporate Social Responsibility
CORPORATE SOCIAL RESPONSIBILITY Company are committed to the protection of environment and investing in community’s health and education. During the year ended 30 June 2024, Company has contributed to various CSR activities including: Through collaboration Company has Company annually supports with
Slide 11: Agenda
AGENDA 1. Company Profile 2 Collaborations and Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session
Slide 12: Collaborations
COLLABORATIONS Grupo Empresarial 1 Bago S.A. 4 BioGaia Sweden 5 Nihon Kohden 2 Boston Scientific 3 Gilead Sciences PEOPLE TRUST US
Slide 13: Product Portfolio – Pharma
PRODUCT PORTFOLIO – PHARMA Our key therapeutic areas include: 1 Gastroenterology 2 Diabetes / Anti-Obesity 3 Cardiology 4 Hepatology 5 Urology 6 Pediatric 7 Antivirals / Infectious Diseases PEOPLE TRUST US
Slide 14: Product Portfolio – Medical Devices
PRODUCT PORTFOLIO – MEDICAL DEVICES Medical devices of following segments are marketed: 1 Cardiology 2 Endo 3 Urology 4 Electrophysiology 5 Cardiac Rhythm Management 6 Neuromodulation 7 Ultrasound / Other Diagnostic Machines PEOPLE TRUST US
Slide 15: Agenda
AGENDA 1. Company Profile 2 Collaborations and Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session
Slide 16: Pharmaceutical Industry Highlights
PHARMACEUTICAL INDUSTRY HIGHLIGHTS 1 Market Size Overall Pakistan’s Retail Pharma Market stands at Rs. 962.5 Billion. Growth and Growth over last year stands at 21.8%, whereas last 5 years CAGR stands 2 CAGR at 18.6%. Approx. 95% market share is held by top 78 pharma corporates in 3 Top Corporates P
Slide 17: Agenda
AGENDA 1. Company Profile 2 Collaborations and Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session
Slide 18: Financial Performance – Year Ended Jun 2024 (Standalone)
FINANCIAL PERFORMANCE – YEAR ENDED 30 JUN 2024 (STANDALONE) Revenue – net (Rs. Million) Overall topline of the Company grew by 28% over the Revenue last year. Five year CAGR is 19%. 13,500 13,000 12,712 12,500 Gross profit closed at Rs. 4,942 million, compared to 12,000 Gross Rs. 3,822 million last
Slide 19: Financial Performance – Period Ended Sep 2024 (Standalone)
FINANCIAL PERFORMANCE – PERIOD ENDED 30 SEP 2024 (STANDALONE) Revenue – net Overall topline of the Company declined by 7% over the (Rs. Million) same period last year. In-market generic sales increased Revenue by 19% whereas institutional sales of generics and medical 4,000 devices declined by 40%.
Slide 20: Agenda
AGENDA 1. Company Profile 2 Collaborations and Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session
Slide 21: Thank You
De Babul SEE Taebe THANK YOU
Ferozsons Laboratories — Investor Presentation (November 2024) on 6ix